These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 7544174)
1. Alpha 1-blockers vs 5 alpha-reductase inhibitors in benign prostatic hyperplasia. A comparative review. Andersen JT Drugs Aging; 1995 May; 6(5):388-96. PubMed ID: 7544174 [TBL] [Abstract][Full Text] [Related]
2. [Drug therapy of benign prostatic hyperplasia. Is combination therapy with 5 alpha-reductase inhibitors and alpha-receptor blockers effective?]. Horninger W; Bartsch G Urologe A; 2002 Sep; 41(5):442-6. PubMed ID: 12426860 [TBL] [Abstract][Full Text] [Related]
3. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard? Silva J; Silva CM; Cruz F Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531 [TBL] [Abstract][Full Text] [Related]
4. Medical treatment of benign prostatic hyperplasia: 5 alpha-reductase inhibitors and alpha-adrenergic antagonists. Monda JM; Oesterling JE Mayo Clin Proc; 1993 Jul; 68(7):670-9. PubMed ID: 7688840 [TBL] [Abstract][Full Text] [Related]
6. A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia. Ekman P Drug Saf; 1998 Mar; 18(3):161-70. PubMed ID: 9530536 [TBL] [Abstract][Full Text] [Related]
7. [The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia]. Djavan B; McConnell J Wien Med Wochenschr; 1996; 146(8):165-8. PubMed ID: 8767401 [TBL] [Abstract][Full Text] [Related]
8. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. Fwu CW; Eggers PW; Kirkali Z; McVary KT; Burrows PK; Kusek JW J Urol; 2014 Jun; 191(6):1828-34. PubMed ID: 24342143 [TBL] [Abstract][Full Text] [Related]
9. [Benign hypertrophy of the prostate: which treatment, for whom?]. Schulman C Rev Med Brux; 1999 Sep; 20(4):A212-8. PubMed ID: 10523895 [TBL] [Abstract][Full Text] [Related]
10. [Combination drug therapy in patients with BPH]. Kuzmenko AV; Kuzmenko VV; Gyaurgiev TA Urologiia; 2018 Mar; (1):101-105. PubMed ID: 29634142 [TBL] [Abstract][Full Text] [Related]
11. The role of combination medical therapy in benign prostatic hyperplasia. Greco KA; McVary KT Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123 [TBL] [Abstract][Full Text] [Related]
12. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Bartsch G; Rittmaster RS; Klocker H Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065 [TBL] [Abstract][Full Text] [Related]
13. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Naslund MJ; Miner M Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044 [TBL] [Abstract][Full Text] [Related]
15. Combination of α-blocker and 5α-reductase inhibitor for treatment of benign prostatic hyperplasia. Kang D; Hu C; Fu Y; Wang D Clin Invest Med; 2017 Oct; 40(5):E200-E210. PubMed ID: 29061225 [TBL] [Abstract][Full Text] [Related]
16. Medical therapy for benign prostatic hyperplasia: a review of the literature. Clifford GM; Farmer RD Eur Urol; 2000 Jul; 38(1):2-19. PubMed ID: 10859436 [TBL] [Abstract][Full Text] [Related]
17. Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo. Roehrborn CG; Casabé A; Glina S; Sorsaburu S; Henneges C; Viktrup L Int J Urol; 2015 Jun; 22(6):582-7. PubMed ID: 25827166 [TBL] [Abstract][Full Text] [Related]